Shanghai, China · Founded 2017 · Privately Held (backing)
Developer of molecular diagnosis technology designed for precision cancer medicine. Ruijing Bio is based in Shanghai, China and was founded in 2017. Its last reported valuation was $109 million in Apr 2022. It has raised $44 million.
Last reported valuation
$109.1M
Oct 2026
Priced at
—
Total raised
$44.0M
Last round
—
Team — not yet on record
No current team members for Ruijing Bio are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Ruijing Bio with a free account
·Watch Ruijing Bio: the Monday email on marks, rounds and moves
